๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

450 POSTER NPI-2358, a novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV522

โœ Scribed by S. Neuteboom; E. Medina; M.A. Palladino; M.A. Spear; G.K. Lloyd; S. Nawrocki

Book ID
119599606
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
64 KB
Volume
6
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

467 Updated efficacy and safety results
467 Updated efficacy and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial
โœ E.B. Garon; J. Neidhart; J.D. Neidhart; F. Kabbinavar; N. Gabrail; M. Ribeiro de ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 45 KB